Immunotherapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
No increased efficacy seen in trial of low-dose total body irradiation for melanoma
February 8th, 2006
A phase II trial of low-dose total body irradiation (LTBI) and subcutaneous interleukin-2 in metastatic melanoma revealed no indication of increased efficacy or altered toxicity. According to a study from Denmark, "Our own experimental data suggests a therapeutic synergism between low-dose total body irradiation (LTBI) and interleukin-2 (IL-2). Patients and methods: Forty-five patients received a maximum of 2 cycles of high dose subcutaneous (s.c.) IL-2 and LTBI." "One treatment cycle included 5 weeks treatment followed by 2 weeks break and composed of a single radiation fraction 0.1 Gy on days 1, 8, 22 and 30 and IL-2: 18 MU X 2 daily s.c. on days 2...
Source: Immunotherapy Weekly (2006-02-08)
|
